Syncona Portfolio Ltd Buys Shares of 16,640,720 Autolus Therapeutics PLC Sponsored ADR $AUTL

Syncona Portfolio Ltd purchased a new position in shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) during the second quarter, HoldingsChannel.com reports. The fund purchased 16,640,720 shares of the company’s stock, valued at approximately $26,625,152,000. Autolus Therapeutics accounts for approximately 100.0% of Syncona Portfolio Ltd’s holdings, making the stock its largest position. Syncona Portfolio Ltd owned 0.06% of Autolus Therapeutics as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Invesco Ltd. boosted its position in shares of Autolus Therapeutics by 53.3% in the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock worth $51,000 after purchasing an additional 11,381 shares in the last quarter. Jane Street Group LLC raised its stake in Autolus Therapeutics by 809.4% in the first quarter. Jane Street Group LLC now owns 102,493 shares of the company’s stock valued at $159,000 after buying an additional 91,222 shares during the last quarter. Geode Capital Management LLC raised its stake in Autolus Therapeutics by 90.5% in the second quarter. Geode Capital Management LLC now owns 164,314 shares of the company’s stock valued at $375,000 after buying an additional 78,058 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Autolus Therapeutics by 41.6% in the second quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company’s stock worth $88,000 after acquiring an additional 11,289 shares in the last quarter. Finally, Bank of America Corp DE grew its stake in shares of Autolus Therapeutics by 2,891.7% during the second quarter. Bank of America Corp DE now owns 975,135 shares of the company’s stock worth $2,223,000 after acquiring an additional 942,540 shares during the last quarter. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Stock Performance

NASDAQ AUTL opened at $2.15 on Monday. Autolus Therapeutics PLC Sponsored ADR has a 1 year low of $1.17 and a 1 year high of $2.43. The company has a debt-to-equity ratio of 1.04, a current ratio of 4.89 and a quick ratio of 4.40. The company has a market capitalization of $572.24 million, a PE ratio of -2.03 and a beta of 2.07. The company has a fifty day moving average of $1.64 and a 200 day moving average of $1.57.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.06. The business had revenue of $45.69 million during the quarter, compared to analysts’ expectations of $38.56 million. Autolus Therapeutics had a negative return on equity of 178.66% and a negative net margin of 238.66%. Research analysts forecast that Autolus Therapeutics PLC Sponsored ADR will post -0.8 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on AUTL. Wall Street Zen upgraded shares of Autolus Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday. Jefferies Financial Group upgraded shares of Autolus Therapeutics to a “strong-buy” rating in a research note on Monday, April 20th. Weiss Ratings raised Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research note on Monday, August 3rd. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $10.00.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.